Long-term prophylaxis with oral anticoagulants (OACs) is now widely recommended by international guidelines to prevent stroke in all patients with atrial fibrillation (AF) without contraindications presenting an independent risk factor for stroke.^[@R1]--[@R3]^
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However, there are several important considerations in the management of patients taking OACs, starting with the initiation of therapy. The initial phase of anticoagulant therapy, especially in patients with newly diagnosed AF, is of concern: early bleeding and thromboembolic risks have been observed to be significantly higher during the first 90 days of therapy in AF patients initiating warfarin.^[@R4]--[@R6]^

Recently, non--vitamin K antagonist (VKA) oral anticoagulants (NOACs), such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban, have been introduced as alternatives to VKAs.^[@R7],[@R8]^

Unlike VKAs, NOACs have 2 fixed-dose regimens: dabigatran and rivaroxaban are usually given at 150 mg twice daily and 20 mg daily, respectively, except in patients with a high bleeding risk for whom the recommended doses are dabigatran 110 mg twice daily in Europe and rivaroxaban 15 mg daily (10 mg daily in Japan in elderly patients or patients with renal dysfunction).^[@R9]--[@R11]^ Large randomized trials have demonstrated the relative safety and efficacy of these agents versus warfarin, but in selected patients with nonvalvular AF (nv-AF)^[@R12]--[@R14]^ and subsequent observational data have provided conflicting results.^[@R15]--[@R19]^ Few of these studies specifically focused on the early phase of therapy,^[@R15],[@R20]^ and most of them were based on Medicare and Danish data. Large postmarketing studies using other databases are needed to better understand the short-term comparative effectiveness and safety of each specific agent and the dosage of NOACs versus VKAs.

At the initiative of the French medicines agency, we therefore conducted an observational study using the French nationwide medico-administrative databases to assess the bleeding and arterial thrombotic risks of dabigatran and rivaroxaban, each compared with VKA, during the early phase of therapy.^[@R21]^ In this article, we focused on newly treated patients with nv-AF.

Methods
=======

Study Design and Data Source
----------------------------

We performed a retrospective propensity-matched cohort study using 2 French nationwide datasets linked by a unique patient identifier:

1.  The French National Health Insurance information system (SNIIRAM), which collects all individualized and anonymous healthcare claims reimbursed by the French National Health Insurance covering the entire French population: this database also contains patient data such as age, sex, vital status, and eligibility for 100% health insurance coverage for serious and costly long-term diseases (LTDs) encoded in the *International Classification of Diseases, 10th Revision* (ICD-10), and healthcare professional characteristics, as well, but does not include outpatient medical indications;

2.  The French Hospital Discharge database (PMSI), which contains discharge diagnoses (ICD-10 codes) and medical procedures for all patients admitted to hospital in France.

This linkage has previously been used to conduct large-scale epidemiological or postauthorization studies.^[@R22],[@R23]^

Study Population
----------------

This study was based on the French National Health Insurance general scheme, covering ≈50 million people. To be eligible for inclusion, patients had to have evidence of continuous general scheme enrolment for a 5-year preindex period.

The index date was the date of first reimbursement for an OAC. New users, defined as patients with no reimbursement for any OAC during the previous 24 months, were assigned to 1 of the 3 treatment groups according to their index OAC: dabigatran or rivaroxaban with both inclusion periods defined between July 20, 2012 (NOAC French market entry date) and November 30, 2012; or VKA with patients included during the same period of 2011. NOAC doses were classified as low (dabigatran 75 mg and 110 mg or rivaroxaban 10 mg and 15 mg) or high (dabigatran 150 mg or rivaroxaban 20 mg).

Patients \<18 years of age, or who were reimbursed for both dabigatran and rivaroxaban or VKA and NOAC on the index date, or who died on the index date, were excluded. Patients presenting a contraindication to treatment (history of valvular heart disease, ongoing cancer treatment, dialysis for end-stage renal disease, hematologic disease or certain immune system disorders considered to be at higher risk of major bleeding (ie, LTD or discharge diagnoses ICD-10 codes D50--D89), hepatic cirrhosis or fibrosis or liver failure, acute bleeding peptic ulcer) were also excluded. Finally, patients undergoing lower limb orthopedic procedures during the 6-week preindex period were excluded, because they were assumed to be treated for primary prevention of venous thromboembolic events (Table I in the online-only Data Supplement).

From the resulting cohort, we identified: (1) patients with nv-AF by using LTD or discharge diagnoses with ICD-10 code I48 or specific procedures during the 4-year preindex period; (2) patients with deep vein thrombosis/pulmonary embolism by using discharge diagnoses (I26, I80 except I80.0, I81, I82) or specific procedures during the 6-week preindex period; (3) outpatients assumed to have nv-AF among the remaining patients with an algorithm by using proxies discriminating AF from deep vein thrombosis/pulmonary embolism with a 95% specificity (age, sex, use of β-blockers, antiarrhythmics, antiplatelets, antihypertensives, Holter/echocardiography procedures, specialty of the first anticoagulant prescriber, and [d]{.smallcaps}-dimer assessment; see online-only Data Supplement).^[@R24]^

Outcomes
--------

The primary end points were (1) hospitalization for bleeding, including intracranial (hospital discharge ICD-10 codes I60, I61, I62, S06.3, S06.4, S06.5, S06.6), gastrointestinal (I85.0, K25.0, K25.2, K25.4, K25.6, K26.0, K26.2, K26.4, K26.6, K27.0, K272, K27.4, K27.6, K28.0, K282, K28.4, K28.6, K29.0, K62.5, K92.0, K92.1, K92.2) and other bleeding (D62, N02, R31, R58, H11.3, H35.6, H43.1, H45.0, H92.2, J94.2, K66.1, M25.0, N92.0, N92.1, N92.4, N93.8, N93.9, N95.0, R04.0, R04.1, R04.2, R04.8, R04.9) and (2) a composite outcome combining hospitalization for bleeding and all-cause mortality.

The secondary end points were (1) hospitalization for ischemic stroke (I63 except for I63.6) or systemic embolism (I74) and (2) a composite outcome combining hospitalization for ischemic stroke or systemic embolism and all-cause mortality. Only principal discharge diagnoses were used to define end points.

Follow-Up
---------

Patients were followed for up to 90 days from the day after the index date until predefined outcome, loss to follow-up (\>2 consecutive months with no reimbursement), death from any cause, end of the year of inclusion, or end of the 90-day follow-up, whichever came first.

Baseline Covariates
-------------------

The following sociodemographic covariates were used: sex, age at initiation of treatment, and the deprivation index of the patient's municipality of residence (divided into quintiles with a sixth group created for patients residing in overseas departments).^[@R25]^ Baseline covariates also included the specialty of the first OAC prescriber and comorbidities or comedications deemed to be risk factors for bleeding or arterial thromboembolic events.

Comorbidities (heart failure, diabetes mellitus, coronary heart disease, dementia, history of stroke or systemic embolism, peripheral vascular disease, chronic kidney disease, history of transient ischemic attack, history of hospitalization for bleeding) were identified by hospital discharge/LTD diagnoses and specific procedures or drug reimbursements (Table I in the online-only Data Supplement). Comedications (antihypertensives, antiarrhythmics, nonsteroidal anti-inflammatory drugs, antiplatelets, lipid-lowering and antiulcer agents, cardiac glycosides, oral corticosteroids, benzodiazepine drugs) were defined as medications dispensed at least once during the 4-month preindex period.

Because smoking status and alcohol abuse were not directly available from the databases, we used reimbursement of nicotine replacement therapy and hospital discharge diagnoses related to tobacco use (ICD-10 F17, Z71.6, and Z72.0) or alcohol abuse (F10, K70, T51 E24.4, G31.2, G62.1, G72.1, I42.6, K29.2, K86.0, Z50.2, Z71.4, and Z72.1). Clinical scores predicting the risk of stroke (CHA~2~DS~2~-VASc) or bleeding (HAS-BLED) in nv-AF patients adapted to medicoadministrative data were calculated.

Statistical Analyses
--------------------

All analyses were performed separately according to type (dabigatran/rivaroxaban) and dose (low/high) of NOACs by using an intent-to-treat approach. A propensity score (PS) matching analysis was performed to create similar treatment groups with respect to observed characteristics. This PS was determined by using a logistic regression model including the covariates listed above as potential confounders, with age as a categorical variable, with the exception of smoking and alcohol abuse, because only a small proportion of tobacco and alcohol users was identified. The CHA~2~DS~2~-VASc and HAS-BLED scores were not included in the PS because most of their clinical characteristics were already taken into account. One NOAC-treated patient was matched to 2 VKA-treated patients on the logit of the estimated PS without replacement.^[@R26]^ We used nearest-neighbor matching within a caliper width equal to 0.2 of the standard deviation of the logit of the PS.^[@R27]^

Before matching, categorical and continuous baseline covariates were compared between NOAC-exposed and VKA-exposed patients using the χ^2^ test and the Wilcoxon test, respectively, and absolute standardized differences, as well. After matching, weighted standardized differences adapted to incomplete many-to-one matching were calculated to assess the balance between NOAC-exposed and their matched VKA-exposed patients.^[@R28]^ Crude incidence rates were calculated, and Cox models with robust sandwich estimates were used to account for the clustering within matched sets.^[@R29]^ Hazard ratios and their 95% confidence intervals were reported.

Two sensitivity analyses were performed to assess the robustness of the findings based on the primary analyses: exclusion of traumatic bleeding events (S06.3, S06.4, S06.5, S06.6), and restriction of the study population to hospitalized or LTD nv-AF patients. Two subgroup analyses according to age (\<75; ≥75) and level of the HAS-BLED score (\<3; ≥3) were also performed for the bleeding events in nv-AF patients.

All statistical analyses were performed by using SAS Enterprise Guide 4.3 software (SAS Institute, Inc, Cary, NC).

Results
=======

Characteristics of the Cohort
-----------------------------

Out of a total of 65 743 VKA new users, 15 400 (23.4%) were excluded because of contraindications and 1771 (2.7%) were excluded because of a lower limb orthopedic procedure. Among the NOAC new users, 3185 (16.8%) of the 18 974 dabigatran patients and 3050 (15.4%) of the 19 815 rivaroxaban patients were excluded because of contraindications and 4149 (21.9%) and 7548 (38.1%), respectively, were excluded because of a lower limb orthopedic procedure. The most frequent contraindication was the exclusion criterion hematologic disease or certain immune system disorders, particularly nutritional anemia. Among the 71 589 eligible patients, 32 807 (45.8%) were identified as having nv-AF (26.9% by ICD-10 I48 or specific procedures and 18.9% by using the algorithm). This population was composed of 19 713 VKA (fluindione: 83.7%, warfarin: 11.8%), 8443 dabigatran (low doses: 69.8%), and 4651 rivaroxaban (low doses: 38.5%) new users (Figure [1](#F1){ref-type="fig"}).

![Study population flow chart. All figures are numbers or percentages of patients. DVT indicates deep vein thrombosis; NOAC, non--vitamin K antagonist oral anticoagulants; PE, pulmonary embolism; and VKA, vitamin K antagonist;](cir-132-1252-g001){#F1}

Baseline patient characteristics, before matching, are shown in Tables II and III in the online-only Data Supplement. Dabigatran and rivaroxaban were more frequently initiated than VKA by cardiologists in private practice. Dabigatran and rivaroxaban users had a lower mean CHA~2~DS~2~-VASc score and fewer comorbidities than VKA users. The mean HAS-BLED score was comparable between NOAC and VKA users. Patients treated with dabigatran 150 mg or rivaroxaban 20 mg were more frequently males, younger, with lower mean HAS-BLED and CHA~2~DS~2~-VASc scores, and much fewer comorbidities than VKA users. Patients initiating low-dose dabigatran or rivaroxaban were more frequently females and older than VKA users. The proportion of antiplatelet users was higher among patients initiating low-dose dabigatran or rivaroxaban.

In the overall study population, the median duration from the start of treatment (from the day after the index date) to the end of follow-up was 87 days (interquartile range, 56--90 days) for the dabigatran/matched VKA cohort and 80 days (interquartile range, 53--90 days) for the rivaroxaban/matched VKA cohort.

Evaluation of Propensity Score Matching
---------------------------------------

All 8443 dabigatran-treated patients and 4651 rivaroxaban-treated patients were matched with at least 1 VKA user, and 89.7% and 100.0% of these patients were matched with 2 VKA users, respectively. For each NOAC dose category, 100% of the patients were matched with 2 VKA users, except for the low-dose dabigatran category, in which 96.3% of patients were matched with 2 VKA users.

Before matching, across all variables included in the PS, the absolute standardized differences ranged from 0.000 to 0.861 for dabigatran and from 0.001 to 0.518 for rivaroxaban. After matching, all standardized differences were \<0.030 and 0.050, respectively, indicating a good balance between treatment groups (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).
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Dabigatran- and VKA-Matched--Treated Patients: Baseline Characteristics According to Treatment Group After Propensity Score Matching
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Rivaroxaban- and VKA-Matched-Treated Patients: Baseline Characteristics According to Treatment Group After Propensity Score Matching
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Association With Primary End Points
-----------------------------------

Table [3](#T3){ref-type="table"} presents the number of bleeding and arterial thromboembolic events, person-years at risk, and crude event rates for each of the combinations of NOAC dose group and their matched VKA-treated patients.

###### 

Events, Person-Years at Risk, and Crude Event Rates Among NOAC New Users and Matched VKA New Users
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No significant difference in bleeding risk was observed between VKA- and dabigatran- or rivaroxaban-treated patients (HR, 0.88; 95% confidence interval, 0.64--1.21 and HR, 0.98; 95% confidence interval, 0.64--1.51, respectively). The bleeding risk was not significantly different in patients exposed to either low or high doses of each NOAC in comparison with patients exposed to VKA (Figure [2](#F2){ref-type="fig"}).

![Hazard ratios for hospitalized bleeding events according to type and dose of NOAC. All figures are hazard ratios and their 95% confidence interval. NOAC indicates non--vitamin K antagonist oral anticoagulants; and nv-AF, nonvalvular atrial fibrillation.](cir-132-1252-g005){#F2}

The incidence of the composite outcome comprising hospitalization for bleeding and death was comparable between VKA and NOAC new users for all NOAC types and doses (Figure [2](#F2){ref-type="fig"}).

The results of sensitivity analyses confirmed those obtained with the primary analyses for both dabigatran and rivaroxaban. No significant difference between NOAC and VKA was observed in the subgroup analyses (Figure [2](#F2){ref-type="fig"}).

Association With Secondary End Points
-------------------------------------

No significant difference was observed between VKA- and dabigatran- or rivaroxaban-treated patients (HR, 1.10; 95% confidence interval, 0.72--1.69 and HR, 0.93; 95% confidence interval, 0.47--1.85, respectively) in terms of arterial thromboembolic events. Analyses according to NOAC doses did not show any increased risk of stroke or systemic embolism. No significant difference in the incidence of the composite outcome comprising stroke, systemic embolism and death was observed according to the various NOAC types and doses (Table [3](#T3){ref-type="table"}; Figure [3](#F3){ref-type="fig"}).

![Hazard ratios for stroke or systemic embolism according to type and dose of NOAC. All figures are hazard ratios and their 95% confidence interval. NOAC indicates non--vitamin K antagonist oral anticoagulants.](cir-132-1252-g006){#F3}

Discussion
==========

In this large-scale, nationwide cohort study, no significant differences were observed between NOAC (dabigatran or rivaroxaban) and VKA in terms of hospitalizations for bleeding or for arterial thromboembolic events during the early phase of anticoagulant therapy among new users with nv-AF. To our knowledge, this is the first study to assess the short-term benefit/risk balance of both dabigatran and rivaroxaban versus VKA using French medico-administrative databases, because previous studies were conducted on Danish and US Medicare data.^[@R15]--[@R20]^ This study also provides insight into French prescribing patterns of dabigatran and rivaroxaban immediately following their approval for stroke prevention in nv-AF. Significant channeling of the new drugs, ie, NOAC over VKA toward a younger and healthier population, was observed, and the channeling of low doses of each NOAC (dabigatran 75/110 mg or rivaroxaban 10/15 mg) over high doses toward older patients with higher bleeding and stroke risks, as well.

The results of this study are consistent with the overall findings of the randomized clinical trials and most of the subsequent observational studies that did not find any evidence for increased stroke or bleeding risks with NOAC in comparison with warfarin in the short to medium term.^[@R7],[@R8],[@R15]--[@R17],[@R20]^ Few observational studies on NOAC have been published to date, and this study is one of the first large incident cohorts to assess rivaroxaban effectiveness and bleeding risks relative to VKA.^[@R17]^ The observed prescribing trends are in line with those described in the available observational studies.^[@R15]--[@R17]^ French prescribing practices appear to be strongly guided by bleeding risk, as suggested by the high proportion of patients who were prescribed low doses, especially dabigatran 75 mg and rivaroxaban 10 mg. These doses have not been approved in the European Union on the basis of clinical judgment, which raises the question of their effectiveness in patients at high risk of stroke.^[@R9],[@R10]^ It should be noted that more than one-third of dabigatran- or rivaroxaban-treated patients were aged 80 and over, a population that was underrepresented in pivotal clinical trials.^[@R7],[@R8]^

Nevertheless, as in the study by Sørensen et al,^[@R15]^ our design focused on the early phase of OAC therapy, bearing in mind that early events can have a major impact on the overall success of treatment, starting with treatment persistence. Although our overall results are reassuring in relation to the initiation of NOACs in nv-AF patients in France with no marked excess thromboembolic or bleeding risk, they also suggest that particular caution is required when initiating NOACs. Indeed, the initiation of VKAs has been shown to be hazardous owing to the increased risks of bleeding and stroke, which may partly explain the reported underuse of anticoagulant therapy in nv-AF.^[@R4]--[@R6],[@R20]^ But, on the basis of this study comparing NOAC with VKA, NOACs cannot be considered to be safer than VKA during the early phase of treatment. On the contrary, the clinical implications of our results are that physicians must be just as cautious when initiating NOACs as when initiating VKAs, particularly in view of the absence of an antidote and objective monitoring of the extent of anticoagulation. However, one should keep in mind when initiating OAC therapy that good anticoagulation control is difficult to achieve and maintain with VKA: the quality of anticoagulation in warfarin-treated patients with AF has been reported to be suboptimal by many authors in the real-word setting,^[@R30]--[@R32]^ with the corresponding significantly increased risk of adverse clinical outcomes.^[@R33],[@R34]^

Because of the observational design and the 2 existing dosage regimens of NOAC, residual confounding by indication is a particular concern in this study.^[@R35]^ Various techniques were used to mitigate this bias. First, we excluded patients with no nv-AF or with contraindications to avoid artificially biasing the treatment effect by ineligible populations or inappropriate treatment indications. Exclusion of these patients could partly explain the apparent discrepancy between our results and those of a recent study based on Medicare data, in which no exclusions were reported.^[@R18]^ Second, VKA-treated patients were selected in 2011, a period during which NOACs could not be prescribed in France for stroke prevention in nv-AF. Third, analyses were restricted to low and high doses with consistent results.^[@R36]^ Finally, the use of PS matching provides one of the best conditions for nondifferential comparison between NOAC and VKA.^[@R26]--[@R29]^ Moreover, variables of the PS would be expected to be strong confounders. However, PS matching did not control for unobserved factors. Because this study was based on administrative data, confounders such as lifestyle or alcohol consumption and differences between severity levels of certain diseases such as renal impairment were not taken into account. Residual confounding therefore cannot be excluded.

Identifying AF on the basis of administrative data is challenging and a source of selection bias. We therefore used a highly specific algorithm to more accurately identify treated AF outpatients.^[@R24]^ The results are consistent with those obtained on patients identified only by I48 ICD-10 code or specific procedures.

Outcome misclassification, although nondifferential, also constitutes a limitation, because the external validity of the ischemic stroke and bleeding diagnosis codes have not been previously assessed in the French PMSI database. However, only primary hospital discharge diagnoses were used to define outcomes. Furthermore, this database is used to calculate payments for acute inpatient care with internal and external quality control processes.

Intention-to-treat analysis was performed because of the short-term follow-up and the use of medico-administrative databases. The accuracy of this approach to estimate the treatment assignment effect could be open to criticism, because exposure to treatment was based on pharmacy claims, which do not indicate how the patient actually takes the medications.

With a maximum 3-month follow-up period, our study only captured early events. The outcomes studied are rare events, and the small number of events in this study may not have allowed identification of small-to-moderate differences between groups. Because the study was conducted at the time of the introduction of NOACs for nv-AF patients in France, time-varying characteristics of both patients and prescribers cannot be ruled out. Finally, a much longer follow-up would be necessary to assess the long-term benefit-risk balance of NOACs versus VKAs, especially for arterial thromboembolic events.

In conclusion, in this study based on medico-administrative data, no statistically significant difference was observed between NOACs, dabigatran or rivaroxaban, and VKAs in terms of the risk of bleeding or arterial thromboembolic events during the early phase of anticoagulant therapy in nv-AF patients. The same level of clinical caution is therefore required when initiating either NOACs or VKAs. Similar analyses should be extended to other NOACs such as apixaban, and observational studies should now focus on NOAC head-to-head comparison in a noninferiority design.
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CLINICAL PERSPECTIVES {#s1}
=====================

The non--vitamin K antagonists (VKA) oral anticoagulants (NOACs), such as the direct thrombin inhibitor dabigatran and the factor Xa inhibitor rivaroxaban, have provided patients who have atrial fibrillation with a convenient, fixed-dose alternative to VKAs. Although NOACs might have some advantages over VKAs, some concerns have emerged about their safety. Few real-world data has been reported so far, and few studies have specifically focused on the early phase of therapy. However, early bleeding and thromboembolic risks have been observed to be significantly higher during the first 90 days of therapy in patients who have atrial fibrillation initiating warfarin. We therefore conducted a large postmarketing study using the French medicoadministrative databases to better investigate the short-term comparative effectiveness and safety of each specific agent of NOAC versus VKA. In this nationwide propensity-matched cohort study (8443 dabigatran- and 4651 rivaroxaban-treated patients matched with at least 1 VKA user), no significant difference between NOAC (dabigatran or rivaroxaban) and VKA was found in terms of hospitalizations for bleeding or for arterial thromboembolic events during the early phase of therapy among new users with nonvalvular atrial fibrillation. Physicians must therefore be as cautious when initiating NOACs as when initiating VKAs, particularly in view of the absence of a NOAC antidote and objective monitoring of the extent of anticoagulation. These results are consistent with those from the few observational studies published to date and offer clinicians a more comprehensive picture of the NOAC benefit-risk balance during the early phase of treatment.
